|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Michael_Severino
|
|
gptkbp:employs
|
over 200 people
|
|
gptkbp:focusesOn
|
genetic medicine
gene writing
|
|
gptkbp:foundedYear
|
2018
|
|
gptkbp:founder
|
gptkb:Flagship_Pioneering
|
|
gptkbp:fundedBy
|
$230 million (2021 Series B)
|
|
gptkbp:headquartersLocation
|
gptkb:Somerville,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tessera Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:logo
|
Tessera Therapeutics logo.svg
|
|
gptkbp:mission
|
cure disease by writing and rewriting the code of life
|
|
gptkbp:notableInvestment
|
gptkb:Qatar_Investment_Authority
gptkb:SoftBank_Vision_Fund_2
gptkb:Fidelity_Management_&_Research_Company
|
|
gptkbp:parentCompany
|
gptkb:Flagship_Pioneering
|
|
gptkbp:platform
|
gene writing
|
|
gptkbp:researchInterest
|
genetic diseases
therapeutic genome engineering
|
|
gptkbp:website
|
https://www.tesseratherapeutics.com/
|
|
gptkbp:bfsParent
|
gptkb:Alexandria_Venture_Investments
gptkb:Osage_University_Partners
|
|
gptkbp:bfsLayer
|
6
|